Articles

AstraZeneca’s Foray into Parp Inhibitors Started in 2006

AstraZeneca stands to benefit greatly from the successful studies, to date, on the use of Parp Inhibitors in the treatment of cancer. The targeted treatment received mass publicity in June 2009 when a study came out showed great promise and results. So how did AstraZeneca become involved with parp inhibitors? In 2006, AstraZeneca acquired a …

AstraZeneca’s Foray into Parp Inhibitors Started in 2006Read More »